JP2011503094A - 抗ｂ因子抗体およびそれらの使用 - Google Patents

抗ｂ因子抗体およびそれらの使用 Download PDF

Info

Publication number
JP2011503094A
JP2011503094A JP2010533241A JP2010533241A JP2011503094A JP 2011503094 A JP2011503094 A JP 2011503094A JP 2010533241 A JP2010533241 A JP 2010533241A JP 2010533241 A JP2010533241 A JP 2010533241A JP 2011503094 A JP2011503094 A JP 2011503094A
Authority
JP
Japan
Prior art keywords
antibody
factor
sequence
complement
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010533241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503094A5 (enExample
Inventor
ローラ デフォーグ，
ルックレン カンパーニュ， メノ バン
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011503094(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2011503094A publication Critical patent/JP2011503094A/ja
Publication of JP2011503094A5 publication Critical patent/JP2011503094A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010533241A 2007-11-08 2008-11-06 抗ｂ因子抗体およびそれらの使用 Pending JP2011503094A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08
PCT/US2008/082621 WO2009061910A1 (en) 2007-11-08 2008-11-06 Anti-factor b antibodies and their uses

Publications (2)

Publication Number Publication Date
JP2011503094A true JP2011503094A (ja) 2011-01-27
JP2011503094A5 JP2011503094A5 (enExample) 2012-11-15

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533241A Pending JP2011503094A (ja) 2007-11-08 2008-11-06 抗ｂ因子抗体およびそれらの使用

Country Status (15)

Country Link
US (4) US8158762B2 (enExample)
EP (1) EP2209807A1 (enExample)
JP (1) JP2011503094A (enExample)
KR (1) KR20100105587A (enExample)
CN (1) CN101918444A (enExample)
AR (1) AR069233A1 (enExample)
AU (1) AU2008323939A1 (enExample)
BR (1) BRPI0820343A2 (enExample)
CA (1) CA2704973A1 (enExample)
CL (1) CL2008003313A1 (enExample)
IL (1) IL205577A0 (enExample)
MX (1) MX2010005115A (enExample)
PE (1) PE20091022A1 (enExample)
TW (1) TW200927170A (enExample)
WO (1) WO2009061910A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
TWI407953B (zh) * 2011-03-24 2013-09-11 高雄醫學大學 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
AU2017246794B2 (en) 2016-04-04 2024-07-04 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
TWI900560B (zh) 2020-04-20 2025-10-11 美商健臻公司 人類化抗補體因子bb抗體及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103288A2 (en) * 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
WO2007056227A2 (en) * 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
WO2007103549A2 (en) * 2006-03-08 2007-09-13 Archemix Corp. Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
WO2008106644A2 (en) * 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103288A2 (en) * 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
WO2007056227A2 (en) * 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
WO2007103549A2 (en) * 2006-03-08 2007-09-13 Archemix Corp. Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
WO2008106644A2 (en) * 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5010015143; ＵＥＤＡ，Ａ．　ｅｔ　ａｌ．: 'Ｐｒｏｂｉｎｇ　ｆｕｎｃｔｉｏｎａｌ　ｓｉｔｅｓ　ｏｎ　ｃｏｍｐｌｅｍｅｎｔ　ｐｒｏｔｅｉｎ　Ｂ　ｗｉｔｈ　ｍｏｎｏｃｌｏｎａｌ　ａｎｔｉｂｏｄｉｅｓ．　Ｅｖｉｄｅｎｃｅ　ｆｏｒ　Ｃ３ｂ-ｂｉｎｄｉｎ' Ｊ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１３８，　Ｎｏ．４, 19870215, ｐｐ．１１４３-９, ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＯＦ　ＩＭＭＵＮＯＬＯＧＩＳＴＳ *
JPN6013041129; ＣＬＡＲＤＹ，Ｃ．Ｗ．: 'Ｃｏｍｐｌｅｍｅｎｔ　ａｃｔｉｖａｔｉｏｎ　ｂｙ　ｗｈｏｌｅ　ｅｎｄｏｔｏｘｉｎ　ｉｓ　ｂｌｏｃｋｅｄ　ｂｙ　ａ　ｍｏｎｏｃｌｏｎａｌ　ａｎｔｉｂｏｄｙ　ｔｏ　ｆａｃｔｏｒ　Ｂ．' Ｉｎｆｅｃｔ．　Ｉｍｍｕｎ． Ｖｏｌ．６２，　Ｎｏ．１０, 199410, ｐｐ．４５４９-５５ *
JPN6013041132; ＨＯＵＲＣＡＤＥ，Ｄ．Ｅ．　ｅｔ　ａｌ．: 'Ａｎａｌｙｓｉｓ　ｏｆ　ｔｈｅ　ｓｈｏｒｔ　ｃｏｎｓｅｎｓｕｓ　ｒｅｐｅａｔｓ　ｏｆ　ｈｕｍａｎ　ｃｏｍｐｌｅｍｅｎｔ　ｆａｃｔｏｒ　Ｂ　ｂｙ　ｓｉｔｅ-ｄｉｒｅｃｔｅｄ　ｍｕｔａｇｅｎｅｓｉｓ．' Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ． Ｖｏｌ．２７０，　Ｎｏ．３４, 19950825, ｐｐ．１９７１６-２２ *
JPN6013041134; ＯＰＰＥＲＭＡＮＮ，Ｍ．　ｅｔ　ａｌ．: 'Ｑｕａｎｔｉｔａｔｉｏｎ　ｏｆ　ｃｏｍｐｏｎｅｎｔｓ　ｏｆ　ｔｈｅ　ａｌｔｅｒｎａｔｉｖｅ　ｐａｔｈｗａｙ　ｏｆ　ｃｏｍｐｌｅｍｅｎｔ　（ＡＰＣ）　ｂｙ　ｅｎｚｙｍｅ-ｌｉｎｋｅｄ　ｉｍｍｕｎｏｓｏｒ' Ｊ．　Ｉｍｍｕｎｏｌ．　Ｍｅｔｈｏｄｓ Ｖｏｌ．１３３，　Ｎｏ．２, 19901019, ｐｐ．１８１-９０ *

Also Published As

Publication number Publication date
AR069233A1 (es) 2010-01-06
AU2008323939A1 (en) 2009-05-14
CN101918444A (zh) 2010-12-15
CL2008003313A1 (es) 2010-02-05
BRPI0820343A2 (pt) 2017-08-22
US20180037667A1 (en) 2018-02-08
EP2209807A1 (en) 2010-07-28
PE20091022A1 (es) 2009-07-16
CA2704973A1 (en) 2009-05-14
WO2009061910A1 (en) 2009-05-14
MX2010005115A (es) 2010-05-27
IL205577A0 (en) 2010-11-30
US8158762B2 (en) 2012-04-17
US20090123469A1 (en) 2009-05-14
KR20100105587A (ko) 2010-09-29
US20120230997A1 (en) 2012-09-13
US20160024224A1 (en) 2016-01-28
TW200927170A (en) 2009-07-01

Similar Documents

Publication Publication Date Title
JP5416695B2 (ja) 補体が関係している眼の状態の予防および治療
JP5980249B2 (ja) 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
US20180037667A1 (en) Anti-factor b antibodies and their uses
CN102066419A (zh) 人源化抗因子d抗体及其用途
AU2017254945A1 (en) Prevention and treatment of complement-associated eye conditions
AU2013213753A1 (en) Prevention and treatment of complement-associated eye conditions
HK1139161B (en) Prevention and treatment of complement- associated eye conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140418